

EXTENDED SPECTRUM BETA-LACTAMASE PRODUCING ENTEROBACTERIACEAE IN WELL-WATER IN ORU

AMBALI, STEPHEN OLUMIDE

ABSTRACT: Beta-lactam antibiotics are the largest and most commonly used group of antimicrobial agents world-wide. They show very good tolerability and many of the drugs can be administered orally. Bacteria expressing extended-spectrum beta-lactamases (ESBLs), enzymes hydrolysing penicillins and cephalosporins, may not respond to therapy using some of these antibiotics. The isolates are also often co-resistant to other antimicrobial agents, thus further limiting treatment options. Of the 36 isolates collected from well water in Oruljebu, Ogun State and screened using Gram's staining technique, 7 (19.44%) were Gram positive while 29 (80.56%) were Gram negative. Out of the Gram's negatives, 23 were identified as members of the enterobacteriaceae family. Of the 23 enterobacterial isolates subjected to ESBL detection using DDST, one was

found to be positive which is *Vibrio cholerae*. In conclusion this research work shows that the prevalence of ESBL producing Enterobacteriaceae in well water in Oruljebu, Ogun state was very low. Antibiotics sensitivity test reveals that ciprofloxacin, ceftaxidime, cefuroxime, gentamycin, cefotaxime, ofloxacin, nitrofurantoin shows inhibition to *Vibrio cholerae*, while there is inhibition to other enterobacteriaceae at varying degree. All isolates show resistance to augmentin while all are susceptible to gentamycin. A majority of the isolates were multiresistant

KEYWORDS: microorganism, enterobacteriaceae, oru, microbes, beta-Lactam

INTRODUCTION

Extended spectrum β -lactamases (ESBLs) are enzymes that confer variable level of resistance to oximinocephalosporins such as ceftaxime, ceftazidime and monobactams. They occur predominantly in the family enterobacteriaceae with *Klebsiella pneumoniae* been the most commonly reported worldwide and it is responsible for 5-20% of outbreaks of nosocomial infections in intensive care units, burn, oncology and neonatal units (Kotra et al., 2002).

At present there exist more than 200 different natural variants worldwide which constitute serious threat to current β -lactam therapies and represent major therapeutic challenges for clinicians (Lin et al., 2005).

Antibiotic resistance in Gram-negative rods is an increasing problem worldwide. Since the introduction of broad-spectrum cephalosporins into clinical practice in the early 1980s, the selective pressure of the use and overuse of antibiotics has resulted in the emergence and rapid development of resistance to expanded spectrum beta-lactam antibiotics (Paterson and Bonomo, 2005; Bradford 2001). Numerous outbreaks of infection with organisms producing extended-spectrum beta-lactamases (ESBLs) have been observed in many countries throughout the world (Bradford, 2001, Paterson et al., 2001), and these organisms have achieved notoriety for causing nosocomial infections that lead to prolonged hospital stay, increased morbidity and mortality, and consequently increased health-care associated costs (Lee et al., 2006; Wollheim et al., 2011).

Since the description of the first ESBL from Germany in 1983 (Knothe et al., 1983), a steady increase in resistance against cephalosporins has been observed (Bradford 2001; Knothe et al., 1983). ESBLs evolved via point mutations of key amino acids in parent, broad spectrum beta-lactamases (TEM-1, TEM-2 and SHV-1). They have an extended spectrum profile that permits hydrolysis of oximinocephalosporins and monobactams but not 7-alpha-methoxy- cephalosporins (cephamycins). They are generally inhibited by beta-lactamase inhibitors such as clavulanic acid, sulbactam and tazobactam (Paterson and Bonomo, 2005; Bradford, 2001).

Objectives of Study

- To detect the presence or otherwise of ESBL-producing enterobacteriaceae in well water.
- To discuss transmission
- To provide screening methods

- To identify infection control measures

LITERATURE REVIEW

One of the currently most important resistance mechanisms in Enterobacteriaceae, which reduces the efficacy of modern expanded-spectrum cephalosporins is based on the plasmid mediated production of enzymes that inactivate these compounds by hydrolyzing their β -lactam ring. Such resistance is caused by an increasing number of different point-mutational variants of classical broad-spectrum β -lactamases (BSBL), the so-called extended spectrum β -lactamases (ESBLs). Many ESBLs are members of TEM and SHV β -lactamase families, whereas other groups, such as CTX-M, OXA, and PER β -lactamases have been described more recently (Coque et al., 2008, Bush et al., 2005). Since the first description of ESBL-producing Enterobacteriaceae from hospitalized humans, many nosocomial outbreaks and later also community-associated infections have been reported worldwide (Paterson et al., 2005). Recently, ESBL-producing strains have also emerged in healthy human carriers (Geseret et al., 2012), in healthy food-producing animals (Cortés et al., 2010, Geseret et al., 2012) and household pets (Ewers et al., 2011) as well as on food products like meat, fish and raw milk (Geseret et al., 2012).

Carbapenemases are a diverse group of β -lactamases belonging to the Ambler classes A, B and D or Bush groups 2f, 3 and 2d, accordingly (Bush et al., 2005) which even inactivate carbapenems. Class A carbapenemases (Bush group 2f) include the serine β -lactamases NmcA, Sme, IMI-1 and SFC-1 which are chromosomally encoded, as well as the clinically common plasmid encoded KPC enzymes. Carbapenemases of this class are inhibited by clavulanic acid. Class B carbapenemases (Bush group 3) comprise the integron-encoded VIM-types, the IMP, GIM-1, SPM-1- and SIM-types of enzymes, and the plasmid encoded NDM-1 carbapenemase. These metallo- β -lactamases are inhibited by EDTA but not by clavulanic acid. Class D (Bush group 2d) consists of OXA-48 type carbapenemases, which are plasmid encoded, and not inhibited by EDTA and not or only weakly inhibited by clavulanic acid. In the last five years, Carbapenemase-producing Enterobacteriaceae have been increasingly reported in humans world-wide (Nordmann et al., 2011). Moreover, recent data prove that also pigs (Fischer et al., 2012) and cattle (Poirelet et al., 2012) constitute in some countries a possible reservoir of carbapenemase producers.

A worrisome aspect is the spread of ESBL- and carbapenemase producers into the environment especially water bodies. Rivers are considered to be of special importance as a reservoir of resistance genes since they are recipients

University of Wisconsin-Madison, USA,

Correspondence Author : Ambali, Stephen Olumide, University of Wisconsin-Madison, USA, Email : ambalistick@gmail.com, futuremicrobiology2020@gmail.com



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

of bacteria from different sources. ESBLs undergo continuous mutations, causing the development of new enzymes showing expanded substrate profiles (Ewers et al., 2011).

Biological Characteristics of Extended-Spectrum β -Lactamases (ESBLs)

A recent extensive review discussing the molecular characterisation of ESBLs has been published by Bradford. (Bradford, 2001) Currently, β -lactamases are defined through the classification scheme proposed by Bush and colleagues that is based on molecular characteristics of the gene and enzyme rather than phenotypic hydrolysis characteristics alone. (Bush et al., 1995) ESBLs, which have been isolated from a wide variety of Enterobacteriaceae, (Bradford, 2001) as well as *Pseudomonas aeruginosa* (Mugnier et al., 1996; Naas et al., 1997) and Capnocytophagaceae, (Rosenau et al., 2000) are strictly defined as β -lactamases capable of hydrolyzing penicillins, broad- and extended-spectrum cephalosporins, and monobactams, and are inhibited by clavulanic acid (functional group 2b as defined by Bush-Jacoby-Medeiros). These phenotypic characteristics differentiate ESBLs from AmpC type β -lactamases, which are another group of enzymes that are commonly isolated from extended-spectrum cephalosporin-resistant Gram-negative bacteria. AmpC β -lactamases are typically encoded on the chromosome of many Gram-negative bacteria including *Escherichia coli*, *Citrobacter freundii* and *Enterobacter* spp., but can also be found on plasmids. (Philippon et al., 2002) AmpC β -lactamases, in contrast to ESBLs, hydrolyse broad- and extended-spectrum cephalosporins but are not inhibited by clavulanic acid or other β -lactamase inhibitors.

TEM-Type ESBLs

The native TEM-1 β -lactamase confers resistance to ampicillin, penicillin and first-generation cephalosporins such as cephalothin. This enzyme, which is responsible for 90% of ampicillin-resistance in *E. coli* isolates, (Livermore, 1995) is also responsible for penicillin resistance in *H. influenzae* and *Neisseria gonorrhoeae*. Mutations within the *bla*TEM-1 structural gene, presumably through antibacterial selection, have allowed the enzyme to expand its hydrolysis capabilities to particular extended-spectrum cephalosporins and aztreonam, while maintaining its original hydrolysis capabilities. TEM-2, the first variant described, differed from TEM-1 through the substitution of a lysine for a glutamine at position 39. However, TEM-2 is not considered an ESBL as the substrate profile is identical to TEM-1. Consequently, amino acid substitutions at 12 separate amino acid positions, acting alone or in concert with other structural gene mutations, have been defined in over 90 described TEM-1- or TEM-2-derived ESBLs. As expected, each TEM-derived ESBL has a slightly different substrate profile in which one ESBL may hydrolyse a specific extended-spectrum cephalosporin more efficiently than another ESBL. Although many ESBLs have subtle differences in substrate profile, these differences cannot be relied upon to differentiate between enzymes and discrimination requires analysis of the amino acid sequence.

SHV-Type ESBLs

The native SHV-1 β -lactamase, found primarily in *K. pneumoniae*, is a plasmid or chromosomally encoded enzyme that confers resistance to penicillins and first-generation cephalosporins. As with TEM-1, specific mutations within the *bla*SHV-1 structural gene expand the hydrolysis capabilities of SHV-1 to extended-spectrum cephalosporins and monobactams. Fewer ESBL variants have been described for SHV-1 than with TEM-1.

Other ESBLs


Other ESBLs have recently been described that are not closely related to TEM-1- or SHV-1-derived enzymes. (Bradford, 2001). These β -lactamases, which are found in a variety of different species within the family Enterobacteriaceae and *P. aeruginosa*, include OXA-type, (Bradford, 2001) CTX-M-type and PER-type (Bradford, 2001) β -lactamases among others. The preferred substrate of these ESBLs differs significantly ranging from cefotaxime (CTX-M-type) to ceftazidime (PER-type).

Although not strictly defined as an ESBL, another group of β -lactamases, called the inhibitor-resistant β -lactamases, have been isolated with increasing frequency. (Veddelet et al., 1992). The inhibitor-resistant β -lactamases are mostly TEM-derived, where 19 separate variants have been described. These TEM

variants are resistant to the inhibition of clavulanic acid and sulbactam, but not tazobactam, and do not hydrolyse extended-spectrum

BETA-LACTAM ANTIBIOTICS

Beta-lactam antibiotics are the largest and most commonly used group of antimicrobial agents in Sweden as well as world-wide. The group is distinguished by a chemical structure known as the beta-lactam ring (figure 1a). Based on their chemical structure they can be divided into four different groups, depending on the ring structure fused to the beta-lactam ring (figure 1b-e), but are often divided into the following groups; penicillins, cephalosporins, carbapenems, monobactam and beta-lactamase inhibitors. (Walsh, 2003)



The beta-lactam antibiotics block the transpeptidation of the cell wall component peptidoglycan, through inhibition of penicillin binding proteins, but exactly how this leads to cell death is not known (Walsh, 2003; Andes et al., 2005; Chambers et al., 2005). Since penicillin binding proteins are not found in cells of the Animalia the toxicity of beta-lactams is very low, but allergy against penicillins and other beta-lactams can be very serious (Weiss et al., 2005). Beta-lactam antibiotics are mainly semi-synthetic compounds, originating from fungi and bacteria found in the environment (Walsh, 2003). More than 80 different beta-lactams are in clinical use, but in Sweden only 23 are marketed (Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01, Antibakteriellamedelförsystemisktbruk. [last accessed 9 Feb 2012]) Some beta-lactams have a very narrow antimicrobial spectrum, while others have a very broad

spectrum and targets both Gram-positive and Gram-negative bacteria.

Resistance against beta-lactams is primarily mediated by a structural change of the penicillin binding proteins (leading to lower affinity of the drug) or by bacterial production of enzymes cleaving the beta-lactam ring. Other mechanisms are decreased permeability or active transportation via efflux pumps. (Chambers et al., 2005)

Penicillins are also called penams and are bicyclic (figure 1b). Penicillin G was one of the first antibiotics to be commercialised in the 1940's. They are divided into sub groups depending on their antimicrobial spectrum and stability against penicillinases, and may be administered orally or parenterally. Penicillins are most often excreted non-metabolised by the kidneys, thus the concentration in urine can reach high levels. (Chambers et al., 2005)

Mecillinam, also known as amidinocillin, is often given as its pro drug pivmecillinam. In Sweden only the oral formula is available (Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01CA08 Pivmecillinam. 2012), and it exerts good activity especially against *E. coli*, *Klebsiella* spp., and *Proteus mirabilis*. The drug is used in the treatment of uncomplicated UTIs. (The Swedish Reference Group for Antibiotics. Pivmecillinam. 2012)

Temocillin is a narrow-spectrum parenteral drug with very limited availability; it is only approved in the UK and Belgium. It is stable against extended-spectrum beta-lactamases (ESBLs) and can be used in the treatment of septicaemia, UTIs and lower respiratory tract infections caused by Enterobacteriaceae. Clinical use has shown that it can be considered as an alternative in treating infections caused by ESBL producing Enterobacteriaceae, primarily UTIs. (Livermore & Tulkens, 2009)

Cephalosporins, or cephems, are also bicyclic (figure 1c). Although discovered earlier, they did not become commercially available until the 1960's. They all show stability against a wide range of beta-lactamases. (Andes et al., 2005) Noteworthy is the ability of emergence of resistance during treatment of Enterobacterspp., Citrobacterspp., Serratiaspp., Morganellaspp., and Providenciaspp. This is due to either spontaneous mutation or up-regulation of the production of naturally occurring beta-lactamases. (Jones et al., 1997; Jacoby, 2009). Cephalosporins can be administered orally, intramuscularly or intravenously, depending on the drug. They are often given empirically in combination with an aminoglycoside or metronidazole (depending on suspected aetiology) for treatment of serious infections such as severe pneumonia, intraabdominal infections, septicaemia or in patients with febrile neutropenia, but it has been widely debated if combination therapy is favourable or not. In everyday language the cephalosporins are classified into "generations", but for clarity this should be avoided scientifically.

Ceftibuten is an oral cephalosporin approved for the treatment of UTIs and acute exacerbations of chronic bronchitis (Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01DD14 Ceftibuten. last accessed 9 Feb 2012) but SRGA only promotes its use for treatment of UTIs. The antimicrobial spectrum includes the urinary tract pathogens *E. coli*, *Klebsiellaspp.* and *Proteus spp.* and some pathogens of the respiratory tract. (The Swedish Reference Group for Antibiotics. Ceftibuten. last accessed 9 Feb 2012)

Ceftazidime shows good activity against several Gram-negative bacteria, including Enterobacteriaceae (especially *E. coli*, *Klebsiellaspp.* and *Proteus spp.*), and *Pseudomonasaeruginosa*. It is administered parenterally and mainly used for treatment of nosocomial pneumonia and in patients with cystic fibrosis, and suspected septicaemia in neutropenic patients.

Cefotaxime is a broad spectrum cephalosporin for parenteral administration, used for the treatment of serious infections in and from internal organs, skin and soft tissues, including meningitis. The antimicrobial spectrum covers a large portion of the Enterobacteriaceae (especially *E. coli*, *Klebsiellaspp.*, *Proteus spp.*, *Salmonella spp.* and *Shigellaspp.*) and several skin and respiratory tract pathogens. (The Swedish Reference Group for Antibiotics. Cefotaxim. last accessed 9 Feb 2012)

Cefepime is a broad spectrum cephalosporin with higher stability against beta-lactamases than the other approved cephalosporins available in Sweden. Thus its antimicrobial spectrum almost completely covers the Enterobacteriaceae, including the members naturally producing beta-lactamases. It is also effective against *P. aeruginosa* and several other Gram-negative non-Enterobacteriaceae, and Gram-positive pathogens of the skin and respiratory tract. It is administered parenterally and the use is mainly treatment of nosocomial pneumonia and suspected septicaemia in neutropenic patients. (The Swedish Reference Group for Antibiotics. Cefepim. 2012)

Carbapenems are bicyclic compounds (figure 1d) that came into use in the 1980's. They show very good stability against beta-lactamases, including many of the ESBLs. In combination with their unique mechanism of outer membrane permeability this results in a very broad spectrum of activity, including Gram-positive and Gram-negative aerobic and anaerobic bacteria. All carbapenems are administered parenterally. (Chambers et al., 2005). Imipenem is always given together with an enzyme inhibitor, cilastatin, preventing its rapid degradation by the kidneys to inactive metabolite (Chambers et al., 2005).

The antibacterial spectrum is very broad and includes *P. aeruginosa*, *Acinetobacterspp.*, most Enterobacteriaceae (not *Proteus spp.*, *Providenciaspp.* or *Morganellaspp.*), *Enterococcus faecalis*, pathogens of the skin and respiratory tract and many anaerobes. The drug is saved for severe infections originating from internal organs and suspected septicaemia

in neutropenic patients, and is effective against infections caused by ESBL producing bacteria, but not against methicillin-resistant staphylococci, *Enterococcus faecium* or *Stenotrophomonasspp.* (The Swedish Reference Group for Antibiotics. Imipenem. 2012)

Meropenem has an antibacterial spectrum similar to that of imipenem, also including *Neisseria meningitidis*, *Proteus spp.*, and *Morganellaspp.* This broadens the use, compared to imipenem, to also include meningitis. The activity against enterococci and *Stenotrophomonasspp.* is insufficient. (The Swedish Reference Group for Antibiotics. Meropenem. 2012)

Ertapenem is a newer carbapenem, with a narrower antibacterial spectrum than the others. It is active against common pathogens of the skin and respiratory tract, Enterobacteriaceae and some anaerobes, but not *P. aeruginosa* or *Acinetobacterspp.* (The Swedish Reference Group for Antibiotics. Ertapenem. 2012). The drug is approved for the treatment of pneumonia, intra-abdominal, acute gynaecological and diabetic foot infections (Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01DH03 Ertapenem. 2012) but the recommendation of SRGA is to save the drug for treatment of cephalosporin resistant Enterobacteriaceae in the polyclinic setting, since it only requires once daily dosing (The Swedish Reference Group for Antibiotics. Ertapenem. 2012).

Monobactams are monocyclic compounds (figure 1e), and aztreonam is the only clinically available drug of this group (Chambers et al., 2005).

The antibacterial spectrum is narrow; it covers aerobic Gram-negative bacteria, and the drug is administered parenterally. Approved indications include gonorrhoea and complicated infections originating from the urinary or respiratory tract. Aztreonam seldom give rise to adverse side effects. (Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01DF01 Aztreonam. 2012)

Beta-lactamase inhibitors show very weak antibacterial activity and are used in combinations with penicillins to act as "suicide substrates". They form stable intermediates, thus capturing and deactivating the beta-lactamases. They are stable against penicillinases, some chromosomal cephalosporinases and some ESBLs. (Chambers et al., 2005)

Amoxicillin-clavulanic acid is a combination whose antibacterial activity covers both Gram-negative and Gram-positive, aerobes and anaerobes, found on various sites such as skin, respiratory tract and saliva. It also exerts effect on parts of the Enterobacteriaceae. The drug is used in the treatment of uncomplicated pneumonia and upper respiratory tract infections, UTIs, and bite wounds. (The Swedish Reference Group for Antibiotics. (Ampicillin/Amoxicillin/Amoxicillinklavulansyra. 2012)

Piperacillin-tazobactam is a parenteral, broad spectrum drug combination used in serious infections such as nosocomial pneumonia, intra-abdominal infections or in patients with febrile neutropenia. The antibacterial spectrum covers pathogens of the skin and respiratory tract, Enterobacteriaceae, *Pseudomonas spp.* and many anaerobes. (The Swedish Reference Group for Antibiotics. Piperacillin-tazobactam. 2012)

SAMPLE COLLECTION AND ANALYSIS

A total of eighteen samples were collected in Oru/Ijebu, Ogun State in three batches of six each. After which the water was taken to the laboratory for microbial analysis.

Serial dilution was done on the water sample and the 10⁻⁵ were used for culturing on MacConkey.

Bacteria were identified by three arrays.

The first one - macroscopic estimation (description of colony).

The second one - microscopic estimation (dyeing by Gram and Schaeffer-Fulton method).

The third one - biochemical tests according to bacteria classification according to Bergey (Holt et al., 1994).

STERILIZATION OF MATERIALS USED

Glassware such as test tubes, pipettes, conical flask, beakers, universal bottles and Bijou bottles were sterilized by washing them with detergents and placed in an oven at 160°C for 3 hours. Foil paper was used to cover opened glassware before they are sterilized. Inoculating loop and needles were sterilized by flaming until red hot and allowed to cool.

GRAM STAINING

The isolates were Gram stained to determine their gram's reaction

- i. A colony from the supposed pure culture to be identified was emulsified in physiological saline water on a grease free slide and allowed to air dry.
- ii. The dried smear was fixed by passing the slide through a Bunsen flaming for 3 minutes
- iii. The dried smear was covered with crystal violet stain for 60 seconds
- iv. The stain was rapidly washed off with clean water.
- v. The water was tipped off and the smear was covered lugor iodine for another 60 seconds.
- vi. The iodine was washed off with clean water.
- vii. The smear was rapidly decolourized with ethanol and immediately washed off with clean water.
- viii. The smear was then covered with safranin for 60 seconds
- ix. The stain was washed off with clear water and left to air dry on a draining rack.
- x. The smear was then examined microscopically under the oil-immersion of the microscope.

BIOCHEMICAL TEST

CATALASE TEST

Principle: This test is used to differentiate the bacteria that produces the enzyme catalase, from non catalase producing bacteria.

Procedure:

A 24 hour old culture was used from nutrient agar and tested for catalase production by bringing it into contact with 3% Hydrogen peroxide on a clean glass slide using a sterile wooden stick.

CITRATE TEST

Citrate method using Simmon's citrate agar

1. Slopes of the medium is prepared in bijou bottles as recommended by the manufacturer (store at 2-8 C).
2. Using a sterile straight wire, a streak on the slope with a saline suspension of the test organism and then the butt is stabbed.
3. And the inoculated bottle is incubate at 35 C for 48 hours. A bright blue colour in the medium indicates positive and retention of the green colour indicate negative result.

OXIDASE TEST

Method:

The edge of microscopic slide was used to pick a colony of the test organisms and placed on a filter paper soaked in 2 to 3 drops of 1 tetremethyl-P phenylenediaminedihydrochloride solutions. A positive reaction is shown by the development of a dark purple colour within 10 seconds, and if there is no dark purple colouration within 10 seconds.

COAGULASE TEST

0.5ml of undiluted plasma was added to about 2ml of peptone water in a bijou bottle that was emulsified with the colony of test organisms, incubated at 37°C for 24 hours. A positive result is indicated with definite clot formation. A negative result indicates number definite a lot of formation.

INDOLE TEST

The test organisms was inoculated into sterile tryptone soy broth and incubated at 37°C for 48 hours. A drop of Kovac's reagent (4-para-dimethylaminobenzaldehyde) was added and the shock gently and observed for colour change at the interphase of the two fluids. A positive result was indicated by the reformation of a pink to red colour. No colour change from pink to red indicates negatives result.

BLOOD AGAR PLATES (BAP)

This is a differential medium. It is a rich, complex medium that contains 5% sheep red blood cells. BAP tests the ability of an organism to produce hemolysins, enzymes that damage/lyse red blood cells (erythrocytes).

∥ Beta-hemolysis is complete hemolysis. It is characterized by a clear (transparent) zone surrounding the colonies.

∥ Partial hemolysis is termed alpha-hemolysis. Colonies typically are surrounded by a green, opaque zone.

If no hemolysis occurs, this is termed gamma-hemolysis. There are no notable zones around the colonies.

ANTIMICROBIAL SUSCEPTIBILITY TESTS

Antimicrobial susceptibility tests were performed as recommended by the Clinical and Laboratory Standards Guidelines (CLSI, 2006) on Mueller Hinton agar plates.

The isolates were cultured on prepared Mueller Hinton Agar (Biotech, England) plates and incubated for at 37°C for 24 hours so as to obtain confluent growth for sensitivity test. Few colonies of isolates from Mueller Hinton plates were dispensed in peptone water and incubated for six hours for sensitivity tests as described by NCCLS (1999).

TEST FOR ESBLs SCREENING

The sensitivity of standard inocula of isolates to Cephoxime (Ce 30µg), Cefadime (Ca 30µg) and Cefazidime/Clavulanic acid (Cac 30µg) (Hi-Media, India) disks was determined on Mueller Hinton Agar (Biotech, India) using Kirby Bueur method (NCCLS, 2002).

RESULTS

Of the 36 isolates collected from the two sampling sites (i.e. well water in Oruljebu, Ogun State) and screened using Gram's staining technique, 7(19.44%) were Gram positive while 29(80.56%) were Gram negative. Out of the Gram's negatives, 23 were identified as members of the enterobacteriaceae family

DISCUSSION AND CONCLUSION

The sites of isolation of the test organisms was Oruljebu, Ogun State. Of the 361 isolates collected from the two sampling sites [i.e. well water in Oruljebu, Ogun state] and screened using Gram's staining technique, 7(19.44%) were Gram positive while 29(80.56%) were Gram negative. Out of the Gram's negatives, 23 were identified as members of the enterobacteriaceae family.

On comparing the occurrence and distribution of enterobacterial isolates with *E. coli*, *Klebsiella*, *Salmonella*, *Proteus*, *Enterobacter*, and *Shigella* species being identified among samples obtained from well water in Oruljebu, amongst which *Escherichia coli* has the highest prevalence (16.67%).

The high occurrence of enterobacteriaceae among the clinical isolates may be due to poor hygienic practices which may result in some of the ESBLs non-producing isolates acquiring plasmids responsible for ESBLs production since plasmids can easily be transferred between organisms living in the same environment and replicate alongside the bacterial chromosome during

reproductive processes (Gunseren et al, 1999).

Of the 23 enterobacterial isolates subjected to ESBL detection using NCCLS breakpoint, one (1) was found to be positive. *E. coli* was confirmed to be ESBL producers based on DDST. In general, the percentage prevalence of ESBLs producers among the different species of enterobacterial isolates screened was seen only in *Vibrio cholera* (4.3%). The low occurrence of ESBLs *E. coli* species observed in this research is not of less concern since infections caused by these organisms though are very common in this part of the country due to the contagious nature and unavailability of qualitative drinking water respectively yet the occurrence is minimal.

RECOMMENDATIONS

In view of the worldwide occurrence and quick spread of ESBLs among bacterial pathogens and the problems that may be caused by treatment failure due to infections with ESBLs producing organisms, it could be recommended that;

Government should strengthen awareness campaigns on improved hygienic practices so as to reduce the rate of microbial infections as well as spread of ESBLs among both enterobacterial and other bacterial pathogens.

REFERENCES

- Andes, D.R. & Craig, W.A. (2005) Cephalosporins. In Principles and practice of infectious disease. Mandell, G.L., Bennett, J.E. & Dolin, R., editors.. London. Elsevier, Churchill. Livingstone. p. 294-311.
- Anonymous. (2008). Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI document M100-S18 2008, Wayne, PA. USA.
- Available from: <http://www.srga.org/ABSPEC/2010/Imipenem%20101216.pdf>.
- Bradford P.A (2001) Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev* 14: 933-951.
- Bradford P.A. (2001) Extended-spectrum β -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev*; 48:933-51
- Bush K, Jacoby G.A., Medeiros A.A. (1995). A functional classification scheme for β -lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother*; 39: 1211-33
- Bush, K., and G.A. Jacoby. 2010. Updated functional classification of beta-lactamases. *Antimicrobial Agents and Chemotherapy* 54:969-976.
- Chambers, H.F. (2005) Penicillins. In Principles and practice of infectious diseases. Mandell, G.L., Bennett, J.E. & Dolin, R., editors. London. Elsevier, Churchill, Livingstone. p. 281-293.
- Chambers, H.F. Other beta-lactam antibiotics, in Principles and practice of infectious diseases. Mandell, G.L., Bennett, J.E. & Dolin, R., editors. 2005. London. Elsevier, Churchill, Livingstone. p. 311-318.
- Chen, H., W. Shu, X. 328 Chang, J. Chen, Y. Guo, and Y. Tan. (2010). The profile of antibiotics resistance and integrons of extended-spectrum beta-lactamase producing thermotolerant coliforms isolated from the Yangtze River basin in Chongqing. *Environmental Pollution* 158:2459-2464.
- Clermont O., S. Bonacorsi, and E. Bingen. (2000). Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Applied and Environmental Microbiology* 66:4555- 4558.
- CLSI (2006). Performance Standards for Antimicrobial Susceptibility Testing: 16th Informational Supplement, pp. M100-S16 (Volume 26, Number 3. Table 2A. Zone diameter interpretive standards and equivalent minimal inhibitory concentration breakpoints for Enterobacteriaceae), Clinical and Laboratory Standards Institute, Wayne, PA.
- Coque T.M., F. Baquero, and R. Canton. (2008). Increasing prevalence of ESBL producing Enterobacteriaceae in Europe. *Eurosurveillance* 13:1-11.
- Cortés, P., V. Blanc, A. Mora, G. Dahbi, J.E. Blanco, M. Blanco, C. Lopez, A. Andreu, F. Navarro, M.P. Alonso, G. Bou, J. Blanco, M. Llagoster. (2010). Isolation and characterization of potentially pathogenic antimicrobial-resistant *Escherichia coli* strains from chicken and pig farms in Spain. *Applied and Environmental Microbiology* 76:2799-2805.
- Ellington, M.J., J. Kistler, D.M. Livermore, and N. Woodford. (2007). Multiplex PCR for rapid detection of genes encoding acquired metallo- β -lactamases. *Journal of Antimicrobial Chemotherapy* 59:321-322.
- Ertapenem. [2012]; Available from: <http://www.fass.se/LIF/>
- Ewers, C., M. Grobbel, A. Bethe, L.H. Wieler, and S. Guenther. (2011). Extended spectrum beta-lactamases-producing gram-negative bacteria in companion animals: action is clearly warranted! *Berliner Munchner Tierarztliche Wochenschrift* 124:94-101.
- Fischer, J., I. Rodríguez, S. Schmogger, A. Friese, U. Roesler, R. Helmuth, and B. Guerra. (2012). *Escherichia coli* producing VIM-1 carbapenemase isolated on a pig farm. *Journal of Antimicrobial Chemotherapy* 67:1793-1795.
- Geser, N., R. Stephan, and H. Hächer. (2012). Occurrence and characteristics of extended spectrum β -lactamases (ESBL) producing Enterobacteriaceae in food producing animals, minced meat and raw milk. *BMC Veterinary Research* 8:21.
- Geser, N., R. Stephan, B.M. Korczak, L. Beutin, and H. Hächler. (2012). Molecular identification of Extended-Spectrum β -lactamase Genes from Enterobacteriaceae isolated from healthy human carriers in Switzerland. *Antimicrobial Agents and Chemotherapy* 56:1609-1612.
- Geser, N., R. Stephan, P. Kuhnert, R. Zbinden, U. Käppeli, N. Cernela, and H. Hächler. (2011). Fecal carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae in swine and cattle at slaughter in Switzerland. *Journal of Food Protection* 74:446-449.
- Gunseren, F., Mamikoglu, L., Ozturk, S., Yucesoy, M., Biberoglu, K., Yulug, N., Doganay, M., Sumerkan, B., Kocagoz, S., Unal, S., Cetin, S., Calangu, S., Koksak, I., Leblebicioğlu, H. and Gunaydin, M. (1999): A surveillance study of antimicrobial resistance of gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey. *J. Antimicrob. Chemother.* 43: 373-378.
- <http://www.srga.org/ABSPEC/2010/Meropenem%20101216.pdf>.
- Jacoby, G.A. AmpC beta-lactamases. *Clin Microbiol Rev* 2009.22(1):161-82.
- Jones, R.N., Baquero, F., Privitera, G., Inoue, M. & Wiedemann, B. (1997). Inducible β -lactamase-mediated resistance to third-generation cephalosporins. *Clin Microbiol Infect.* 3:s7-s20.
- Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S (1983). Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. *Infection* 11: 315-317.
- Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01, Antibakteriellamedelförsystemisktbruk. [last accessed 9 Feb 2012]; Available from: http://www.fass.se/LIF/produktfakta/sok_lakemedel.jsp?expanded=J_J01#J01.
- Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01CA08 Pivmecillinam. [2012]; Available from: http://www.fass.se/LIF/produktfakta/sok_lakemedel.jsp?expanded=J_J01_J01C_J01CA_J01CA08#J01CA08.
- Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01DD14 Ceftributen. [last accessed 9 Feb 2012]; Available from: http://www.fass.se/LIF/produktfakta/sok_lakemedel.jsp?expanded=J_J01_J01D_J01DD_J01DD14#J01DD14.
- Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01DD02 Ceftazidim. [last accessed 9 Feb 2012]; Available from: http://www.fass.se/LIF/produktfakta/sok_lakemedel.jsp?expanded=J_J01_J01D_J01DD_J01DD02#J01DD02.
- Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01DH03

32. Läkemedelsindustriföreningens Service AB. FASS.se, ATC-register, J01DF01Aztreonam. [last accessed 9 Feb 2012]; Available from: http://www.fass.se/LIF/produktfakta/sok_lakemedel.jsp?expanded=J_J01_J01D_J01DF_J01DF01#J01DF01.
33. Lee S.Y., Kotapati S, Kuti J.L., Nightingale C.H., Nicolau D.P. (2006) Impact of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella* species on clinical outcomes and hospital costs: a matched cohort study. *Infect Control Hosp Epidemiol* 27: 1226-1232.
34. Livermore D.M. (1995) β -lactamases in laboratory and clinical resistance. *Clin Microbiol Rev*; 8: 557-84
35. Livermore, D.M. & Tulkens, P.M. (2009). Temocillin revived *J Antimicrob Chemother.* 63(2): 243-5.
36. Mollet, C., M. Drancourt, and D. Raoult. (1997). rpoB sequence analysis as a novel basis for bacterial identification. *Molecular Microbiology* 26: 1005-10011.
37. Mugnier PI, Casin I, Casin G, et al. (1996) A TEM-derived extended spectrum β -lactamase in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*; 40: 2488-93
38. Naas T, Philippon L, Poirel L, et al. (1999). An SHV-derived extended spectrum beta-lactamase in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*; 43: 1281-4
39. Nordmann P., T. Naas, and L. Poirel. (2011). Global spread of Carbapenemase-producing Enterobacteriaceae. *Emerging and Infectious Diseases* 17: 1791-1798.
40. Paterson D.L., Bonomo R.A. (2005) Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev* 18: 657-686.
41. Paterson D.L., Ko W.C., Von Gottberg A, Casellas J.M., Mulazimoglu L, Klugman K.P., Bonomo R.A., Rice L.B., McCormack J.G., Yu V.L. (2001). Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β -lactamases: implications for the clinical microbiology laboratory. *J Clin Microbiol* 39: 2206-2212.
42. Paterson, D.L., and R.A. Bonomo. (2005). Extended-spectrum β -lactamases: a clinical update. *Clinical Microbiological Review* 18: 657-686.
43. Philippon A, Arlet B, Jacoby G.A. (2002) Plasmid-determined AmpC type β -lactamases. *Antimicrob Agents Chemother*; 46: 1-11
44. Pitout, J.D., K.S. Thomson, N.D. Hanson, A.F. Erhardt, E.S. Moland, and C.C. Sanders. (1998). Beta-lactamases responsible for resistance to expanded-spectrum cephalosporins in *Klebsiella pneumoniae*, *Escherichia coli*, and *Proteus mirabilis* isolates recovered in South Africa. *Antimicrobial Agents and Chemotherapy* 42: 1350-1354.
45. Poirel, L., A. Barbosa-Vasconcelos, R.R. Simoes, P.M. Da Costa, W. Liu, and P. Nordmann. (2012). Environmental KPC-Producing *Escherichia coli* isolates in Portugal. *Antimicrobial Agents and Chemotherapy* 56: 1662-1663.
46. Poirel, L., T.R. Walsh, V. Cuvillier, and P. Nordmann. (2011). Multiplex PCR for detection of acquired carbapenemase genes. *Diagnostic Microbiology and Infectious Disease* 70: 119-123.
47. produktfakta/sok_lakemedel.jsp?expanded=J_J01_J01D_J01DH_J01DH03#J01DH03.
48. Rosenau A, Cattier B, Goussset N, et al. (2000). Capnocytophaga ochromacea: characterization of a plasmid encoded extended spectrum TEM-17 β -lactamase in the phylum Flavobacterium Bacteroides. *Antimicrob Agents Chemother*; 44: 760-2
49. The Swedish Reference Group for Antibiotics. Ampicillin/Amoxicillin/Amoxicillinklavulansyra. [2012]; Available from: <http://www.srga.org/ABSPEC/2010/Ampicillin%20101216.pdf>.
50. The Swedish Reference Group for Antibiotics. Cefepim. [last accessed 9 Feb 2012]; Available from: <http://www.srga.org/ABSPEC/2010/cefepim%20101216.pdf>.
51. The Swedish Reference Group for Antibiotics. Cefotaxim. [last accessed 9 Feb 2012]; Available from: <http://www.srga.org/ABSPEC/2010/cefotaxim%20101216.pdf>.
52. The Swedish Reference Group for Antibiotics. Ceftazidim. [last accessed 9 Feb 2012]; Available from: <http://www.srga.org/ABSPEC/2010/ceftazidim%20101216.pdf>.
53. The Swedish Reference Group for Antibiotics. Cefibuten. [last accessed 9 Feb 2012]; Available from: <http://www.srga.org/ABSPEC/2010/Cefibuten%20101216.pdf>.
54. The Swedish Reference Group for Antibiotics. Ertapenem. [2012]; Available from: <http://www.srga.org/ABSPEC/2010/Ertapenem%20101216.pdf>.
55. The Swedish Reference Group for Antibiotics. Imipenem. [last accessed 9 Feb 2012];
56. The Swedish Reference Group for Antibiotics. Meropenem. [2012]; Available from:
57. The Swedish Reference Group for Antibiotics. Piperacillin-tazobactam. [2012]; Available from: <http://www.srga.org/ABSPEC/2010/Piperacillintazobactam%20101216.pdf>.
58. The Swedish Reference Group for Antibiotics. Pivmecillinam. [2012]; Available from: <http://www.srga.org/ABSPEC/2010/Pivmecillinam%20101216.pdf>.
59. Walsh, C. (2003) *Antibiotics: actions, origins, resistance*. Washington DC. ASM Press.
60. Weiss, M.E. & Adkinson, N.F. (2005). Beta-lactam allergy. In *Principles and practice of infectious diseases*. Mandell, G.L., Bennett, J.E. & Dolin, R., editors. London. Elsevier, Churchill, Livingstone. p. 318-326.
61. Wirth, T., D. Falush, R. Lan, F. Colles, P. Mensa, L.H. Wieler, H. Karch, P.R. Reeves, M.C. Maiden, H. Ochman, and M. Achtman. (2006). Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Molecular Microbiology* 60: 1136-1151.
62. Wollheim C, Guerra I.M., Conte V.D., Hoffman S.P., Schreiner F.J., Delamare A.P., Barth A.L., Echeverrigaray S, Costa S.O. (2011) Nosocomial and community infections due to class A extended-spectrum beta-lactamase (ESBLA)-producing *Escherichia coli* and *Klebsiella* spp. in southern Brazil. *Braz J Infect Dis* 15: 138-143.
63. Woodford, N., E.J. Fagan, and M.J. Ellington. (2005). Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β -lactamases. *Journal of Antimicrobial Chemotherapy* 57: 154-155